UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Clinical trials for UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
Disease control Recruiting nowThis Phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (doxorubicin) helps people with advanced dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma live longer without their cancer worsening. About 365 adults whose…
Matched conditions: UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or s…
Matched conditions: UNRESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC